As of today (2024-10-31), Viatris's share price is $11.60.
Viatris's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2024 was $1.56. Hence, Viatris's Price-to-Free-Cash-Flow Ratio for today is 7.43.
The historical rank and industry rank for Viatris's Price-to-Free-Cash-Flow or its related term are showing as below:
VTRS'
s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 3.48 Med: 10.25 Max: 110.59
Current: 7.4
During the past 13 years, Viatris's highest Price-to-Free-Cash-Flow Ratio was 110.59. The lowest was 3.48. And the median was 10.25.
VTRS's Price-to-Free-Cash-Flow is ranked better than 87.38% of 515
companies
in the Drug Manufacturers industry
Industry Median: 25.17
vs VTRS: 7.40
During the past 12 months, the average Free Cash Flow per Share Growth Rate of Viatris was -7.60% per year.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was 28.10% per year.
During the past 5 years, the average Free Cash Flow per Share Growth Rate was -2.00% per year.
During the past 10 years, the average Free Cash Flow per Share Growth Rate was 2.50% per year.
During the past 13 years, Viatris's highest 3-Year average Free Cash Flow per Share Growth Rate was 63.30% per year. The lowest was -42.00% per year. And the median was 11.40% per year.
Viatris Price-to-Free-Cash-Flow Historical Data
The historical data trend for Viatris's Price-to-Free-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Viatris's Price-to-Free-Cash-Flow
For the Drug Manufacturers - Specialty & Generic subindustry, Viatris's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viatris's Price-to-Free-Cash-Flow Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Viatris's Price-to-Free-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Viatris's Price-to-Free-Cash-Flow falls into.
Viatris Price-to-Free-Cash-Flow Calculation
Viatris's Price-to-Free-Cash-Flow ratio for today is calculated as
Viatris's Share Price of today is $11.60. Viatris's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.56.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.
In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.
Be Aware
In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.
Viatris Price-to-Free-Cash-Flow Related Terms
Thank you for viewing the detailed overview of Viatris's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
VTRS has been successfully added to your 